港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

生物医药B类股

426.746

-7.368-1.70%

涨家数：3

跌家数：29

平家数：2

市盈率：- -

高：438.862

开：434.827

低：417.654

收：434.114

成交量：1.06亿

成交额：23.63亿

市值：2,734.85亿

流通市值：2,428.17亿

数据加载中...

礼邦医药-B(09637.HK)公开发售获近千倍认购 6月29日登陆港交所

礼邦医药-B(09637.HK)香港公开发售获963.56倍认购 6月29日上市

沛嘉医疗-B(09996.HK)授出233.28万份购股权

沛嘉医疗-B(09996)授出233.28万份购股权

基石药业-B(02616.HK)6月25日斥资185.33万港元回购42.1万股

基石药业-B(02616)6月25日斥资185.33万港元回购42.1万股

新股暗盘 | 礼邦医药-B(09637)暗盘收涨94% 下周一登陆港交所

药明巨诺-B(02126.HK)委任田丰为主席

药明巨诺-B(02126)委任田丰为主席

GIC Private Limited增持歌礼制药-B(01672.HK)479.7万股每股作价约9.98港元

雷平在上海调研脑机接口医疗器械创新发展工作

万邦医药(301520.SZ)拟收购赛德盛75.52%股权进一步完善创新药板块业务布局

智通财经网

归创通桥(02190.HK)6月26日耗资约111.47万港元回购6.4万股

东曜药业-B(01875)：方园获委任为公司联席公司秘书

歌礼制药-B(01672.HK)6月26日斥资192.88万港元回购20万股

诺诚健华(09969)：根据2024年人民币股股份激励计划发行241.83万股新人民币股份

新股暗盘 | 礼邦医药-B(09637.HK)盘初涨76.99% 一手账面赚1740港元

迪哲医药跌6.56% 2021上市中信证券保荐2募资共39亿

沛嘉医疗－Ｂ(09996)股价下跌5.224%，现价港币$3.81

阿斯达克财经

中国创新药抢占全球半壁江山：出海产业价值全面释放高退货、低兑现、同质化困局显现

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1574/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物医药B类股","latestPrice":426.7459,"timestamp":1782461289528,"preClose":434.11383,"halted":0,"volume":106490088,"delay":0,"changeRate":-0.016972,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-7.36792,"latestTime":"06-26 16:00:00","open":434.82693,"high":438.86176,"low":417.65387,"amount":2363000893,"amplitude":0.048853,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782696600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1782437400000,1782446400000],[1782450000000,1782460800000]],"pbRate":3.515767,"peRate":-67.523097,"turnoverRate":0.003771,"increases":3,"decrements":29,"flats":1,"marketCap":273485027840,"floatMarketCap":242817306408},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":438.86176,"amplitude":0.048853,"preClose":434.11383,"low":417.65387,"pbRate":"3.515767","latestPrice":426.7459,"volume":106490088,"delay":0,"open":434.82693,"prevYearClose":556.26263,"prevWeekClose":444.911,"prevMonthClose":544.023,"prevQuarterClose":610.821,"fiveDayClose":444.911,"twentyDayClose":520.536,"sixtyDayClose":579.36,"secType":"PLATE","market":"HK","turnoverRate":0.003771,"peRate":-67.523097,"marketCap":273485027840,"floatMarketCap":242817306408,"timestamp":1782461289528,"nameCN":"生物医药B类股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":3,"down":29,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2646366738","title":"礼邦医药-B(09637.HK)公开发售获近千倍认购 6月29日登陆港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2646366738","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646366738?lang=zh_cn&edition=fundamental","pubTime":"2026-06-26 23:21","pubTimestamp":1782487297,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","BK1515","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646636649","title":"礼邦医药-B(09637.HK)香港公开发售获963.56倍认购 6月29日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2646636649","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646636649?lang=zh_cn&edition=fundamental","pubTime":"2026-06-26 23:07","pubTimestamp":1782486421,"startTime":"0","endTime":"0","summary":"格隆汇6月26日丨礼邦医药-B(09637.HK)公告，公司全球发售56,755,400股H股，每股H股22.60港元，所得款项净额11.81亿港元。香港公开发售股份数目占全球发售股份数目10%，获认购963.56倍；国际发售股份数目占全球发售股份90%，获认购倍19.77倍。\r\n\r\n　　假设全球发售于2026年6月29日(星期一)上午八时正或之前(香港时间)成为无条件，预期H股将于2026年6月29日(星期一)上午九时正(香港时间)开始在联交所买卖。H股将以100股H股为一手买卖单位进行交易，H股的股份代号为09637。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260626/32291951.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1515","09939","09637","BK1574","159938","IPOS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646368265","title":"沛嘉医疗-B(09996.HK)授出233.28万份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2646368265","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646368265?lang=zh_cn&edition=fundamental","pubTime":"2026-06-26 21:53","pubTimestamp":1782481988,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1100","BK1583","09996","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646299368","title":"沛嘉医疗-B(09996)授出233.28万份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2646299368","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646299368?lang=zh_cn&edition=fundamental","pubTime":"2026-06-26 21:53","pubTimestamp":1782481988,"startTime":"0","endTime":"0","summary":"智通财经APP讯，沛嘉医疗-B(09996)发布公告，于2026年6月26日，本公司向若干合资格参与者授出购股权，以供认购本公司合共233.28万股普通股，惟须受限于及遵照本公司于2020年4月28日采纳的购股权计划的条款及条件行事。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459824.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09996","BK1100","159891","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646368329","title":"基石药业-B(02616.HK)6月25日斥资185.33万港元回购42.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646368329","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646368329?lang=zh_cn&edition=fundamental","pubTime":"2026-06-26 21:29","pubTimestamp":1782480581,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","02616","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646368324","title":"基石药业-B(02616)6月25日斥资185.33万港元回购42.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646368324","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646368324?lang=zh_cn&edition=fundamental","pubTime":"2026-06-26 21:29","pubTimestamp":1782480581,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B(02616)发布公告，该公司于2026年6月25日斥资185.33万港元回购42.1万股股份，每股回购价格为4.37-4.41港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459793.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646357850","title":"新股暗盘 | 礼邦医药-B(09637)暗盘收涨94% 下周一登陆港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2646357850","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646357850?lang=zh_cn&edition=fundamental","pubTime":"2026-06-26 20:14","pubTimestamp":1782476058,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，今日辉立暗盘交易显示，港股“肾病创新药第一股”礼邦医药-B(09637)暗盘收报43.88港元，较发售价22.60港元上涨94.16%。每手100股，不计手续费，每手账面赚2128港元。据悉，礼邦医药的IPO引发了全市场的瞩目，公司不仅手握“1 款商业化产品 + 7 款临床阶段候选药物” 的完整管线矩阵，更集齐了横跨全球主权基金、百年资管、专业生命科学基金与产业资本的11家基石投资者，创下近年18A 市场基石阵容的天花板。礼邦医药将于6月29日(星期一)在港交所挂牌。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1161","HEXmain","BK1574","09939","09637","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646635228","title":"药明巨诺-B(02126.HK)委任田丰为主席","url":"https://stock-news.laohu8.com/highlight/detail?id=2646635228","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646635228?lang=zh_cn&edition=fundamental","pubTime":"2026-06-26 20:13","pubTimestamp":1782475981,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02126","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646535223","title":"药明巨诺-B(02126)委任田丰为主席","url":"https://stock-news.laohu8.com/highlight/detail?id=2646535223","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646535223?lang=zh_cn&edition=fundamental","pubTime":"2026-06-26 20:13","pubTimestamp":1782475981,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药明巨诺-B(02126)公布，刘诚博士及Sungwon Song博士各自已自股东周年大会结束后起退任非执行董事。退任生效后，刘诚博士随即不再担任董事会主席，Sungwon Song博士亦不再担任公司薪酬委员会成员。田丰先生已获委任为主席，自2026年6月26日起生效。此次委任后，田丰先生将同时担任公司主席及行政总裁。此外，非执行董事高星女士已获委任为薪酬委员会成员，自2026年6月26日起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459688.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1574","02126","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646352998","title":"GIC Private Limited增持歌礼制药-B(01672.HK)479.7万股 每股作价约9.98港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2646352998","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646352998?lang=zh_cn&edition=fundamental","pubTime":"2026-06-26 19:44","pubTimestamp":1782474242,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","01477","BK1161","01672","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646354626","title":"雷平在上海调研脑机接口医疗器械创新发展工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2646354626","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646354626?lang=zh_cn&edition=fundamental","pubTime":"2026-06-26 19:35","pubTimestamp":1782473736,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1583","159883","BK1100","09996","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646354717","title":"万邦医药(301520.SZ)拟收购赛德盛75.52%股权 进一步完善创新药板块业务布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2646354717","media":"智通财经网","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646354717?lang=zh_cn&edition=fundamental","pubTime":"2026-06-26 19:18","pubTimestamp":1782472705,"startTime":"0","endTime":"0","summary":"万邦医药(301520.SZ)发布公告，公司拟以自有资金或自筹资金3.02亿元收购安徽赛德盛医药科技有限公司(简称“赛德盛”)75.52%股权。交易完成后，赛德盛将成为公司控股子公司。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/astock/22.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/22.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459599.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0216","159992","06978","BK1574","BK1161","301520"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646351282","title":"归创通桥(02190.HK)6月26日耗资约111.47万港元回购6.4万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646351282","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646351282?lang=zh_cn&edition=fundamental","pubTime":"2026-06-26 19:17","pubTimestamp":1782472675,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1587","02190","BK1574","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646351284","title":"东曜药业-B(01875)：方园获委任为公司联席公司秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2646351284","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646351284?lang=zh_cn&edition=fundamental","pubTime":"2026-06-26 19:17","pubTimestamp":1782472626,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东曜药业-B(01875)发布公告，公司联席公司秘书陈一帆先生已辞任其职务，自2026年6月26日起生效。方园女士已获委任为公司联席公司秘书，以接替陈先生，自2026年6月26日起生效，但须满足若干条件，包括公司目前另一名联席公司秘书吕颖一先生将自方女士委任生效之日起计获留任3年。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01875","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646035676","title":"歌礼制药-B(01672.HK)6月26日斥资192.88万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646035676","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646035676?lang=zh_cn&edition=fundamental","pubTime":"2026-06-26 18:23","pubTimestamp":1782469400,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01672","BK1515","01477","BK1574","BK1161","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646840353","title":"诺诚健华(09969)：根据2024年人民币股股份激励计划发行241.83万股新人民币股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2646840353","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646840353?lang=zh_cn&edition=fundamental","pubTime":"2026-06-26 17:16","pubTimestamp":1782465406,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(09969)发布公告，于2026年6月26日，根据2024年人民币股股份激励计划首次授予部分第一个归属期的归属结果向2名董事发行79.5万股新人民币股份(于2024年12月17日采纳)。于2026年6月26日，根据2024年人民币股股份激励计划首次授予部分第一个归属期的归属结果向2名高级管理人员发行20万股新人民币股份(于2024年12月17日采纳)。于2026年6月26日，根据2024年人民币股股份激励计划首次授予部分第一个归属期的归属结果向70名激励对象发行142.23万股新人民币股份(于2024年12月17日采纳)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CYB","MUCmain","BK1574","UCmain","BK0239","09969","BK1161","MCNHmain","688428","CNHmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646330372","title":"新股暗盘 | 礼邦医药-B(09637.HK)盘初涨76.99% 一手账面赚1740港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2646330372","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646330372?lang=zh_cn&edition=fundamental","pubTime":"2026-06-26 16:17","pubTimestamp":1782461863,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","BK1574","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646733761","title":"迪哲医药跌6.56% 2021上市中信证券保荐2募资共39亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2646733761","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646733761?lang=zh_cn&edition=fundamental","pubTime":"2026-06-26 16:03","pubTimestamp":1782460981,"startTime":"0","endTime":"0","summary":"中国经济网北京6月26日讯 迪哲医药 今日收报36.49元，跌幅6.56%。该股目前处于破发状态。　　迪哲医药于2021年12月10日在上交所科创板上市，发行股票4000.01万股，发行价格为52.58元/股。　　迪哲医药首次公开发行股票募集资金总额为21.03亿元，扣除发行费用后募集资金净额为19.87亿元。迪哲医药最终募集资金净额比原计划多2.03亿元。　　迪哲医药2次募资合计募集资金38.99亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260626/32291041.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0188","LU1997244956.HKD","BK1564","BK1147","BK0183","LU1064130708.USD","BK0276","159938","LU1781817850.SGD","06030","LU1255011170.USD","LU1655091616.SGD","LU1997245094.SGD","BK0012","LU1997245177.USD","LU2289578879.USD","IPOS","LU1720050803.USD","09939","LU0405327148.USD","LU1328615791.USD","BK1574","BK1161","BK1516","LU1064131003.USD","LU1794554557.SGD","LU2495084118.USD","LU0405327494.USD","LU1580142542.USD","LU2148510915.USD","BK1515","BK1521","BK0028","BK0196","600030"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646722332","title":"沛嘉医疗－Ｂ(09996)股价下跌5.224%，现价港币$3.81","url":"https://stock-news.laohu8.com/highlight/detail?id=2646722332","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646722332?lang=zh_cn&edition=fundamental","pubTime":"2026-06-26 15:34","pubTimestamp":1782459240,"startTime":"0","endTime":"0","summary":"[下跌股]沛嘉医疗－Ｂ(09996) 股价在下午03:34比前收市价下跌5.224%，现股价为港币$3.81。至目前为止，今日最高价为$3.98，而最低价为$3.81。总成交量为88.4万股，总成交金额为港币$341.268万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725131627024_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725131627024_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2606266111/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2606266111/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","159891","BK1100","BK1583","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646633473","title":"中国创新药抢占全球半壁江山：出海产业价值全面释放 高退货、低兑现、同质化困局显现","url":"https://stock-news.laohu8.com/highlight/detail?id=2646633473","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646633473?lang=zh_cn&edition=fundamental","pubTime":"2026-06-26 15:27","pubTimestamp":1782458820,"startTime":"0","endTime":"0","summary":"　　2025年，中国创新药海外BD交易总额定格在1357亿美元，同比增幅达161%，中国也首次超越美国，占据全球License-out总额的49%。从2020年全年30亿美元的起步规模，到2026年单季度突破600亿美元的交易体量，中国创新药资产的全球价值正在被快速重估。　　但在百亿级交易频出的行业狂欢背后，隐藏在公告数字里的高额水分、居高不下的历史退货率、同质化内卷下的定价权缺失，以及地缘政策的不确定性，也共同构成了出海浪潮下的挑战。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-06-26/doc-inietnfw1966527.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","06978","159992","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":15,"pageCount":1,"totalSize":281,"code":"91000000","status":"200"}]}}